GSK1904529A (CAS 1089283-49-7)
Alternate Names:
GSK-1904529A GSK 1904529A N-(2,6-Difluorophenyl)-5-[3-[2-[[5-ethyl-2-(methyloxy)-4-[4-[4-(methylsulfonyl)-1-piperazinyl]-1-piperidinyl]phenyl]amino]-4-pyrimidinyl]imidazo[1,2-a]pyridin-2-yl]-2-(methyloxy)benzamide CHEMBL466397
CAS Number:
1089283-49-7
Molecular Weight:
852.00
Molecular Formula:
C44H47F2N9O5S
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
GSK1904529A is an inhibitor of IGF-IR.
GSK1904529A (CAS 1089283-49-7) References
- Antitumor activity of GSK1904529A, a small-molecule inhibitor of the insulin-like growth factor-I receptor tyrosine kinase. | Sabbatini, P., et al. 2009. Clin Cancer Res. 15: 3058-67. PMID: 19383820
- Quantitative phosphoproteomics analysis reveals a key role of insulin growth factor 1 receptor (IGF1R) tyrosine kinase in human sperm capacitation. | Wang, J., et al. 2015. Mol Cell Proteomics. 14: 1104-12. PMID: 25693802
- GSK1904529A, an insulin-like growth factor-1 receptor inhibitor, inhibits glioma tumor growth, induces apoptosis and inhibits migration. | Zhou, Q., et al. 2015. Mol Med Rep. 12: 3381-3385. PMID: 26035416
- GSK1904529A, a Potent IGF-IR Inhibitor, Reverses MRP1-Mediated Multidrug Resistance. | Gupta, P., et al. 2017. J Cell Biochem. 118: 3260-3267. PMID: 28266043
- Assessment of GSK1904529A as a promising anti-osteosarcoma agent. | Fei, HD., et al. 2017. Oncotarget. 8: 49646-49654. PMID: 28572530
- Calycosin stimulates the osteogenic differentiation of rat calvarial osteoblasts by activating the IGF1R/PI3K/Akt signaling pathway. | Fang, Y., et al. 2019. Cell Biol Int. 43: 323-332. PMID: 30632644
- Cell Culture Media, Unlike the Presence of Insulin, Affect α-Synuclein Aggregation in Dopaminergic Neurons. | Hlushchuk, I., et al. 2022. Biomolecules. 12: PMID: 35454152
- Upregulation of the ferroptosis-related STEAP3 gene is a specific predictor of poor triple-negative breast cancer patient outcomes. | Yuan, L., et al. 2023. Front Oncol. 13: 1032364. PMID: 37064114
- Advances in lung adenocarcinoma: A novel perspective on prognoses and immune responses of CENPO as an oncogenic superenhancer. | Shi, T., et al. 2023. Transl Oncol. 34: 101691. PMID: 37207381
- Bioinformatics analysis identifies coagulation factor II receptor as a potential biomarker in stomach adenocarcinoma. | Wu, X., et al. 2024. Sci Rep. 14: 2468. PMID: 38291086
Inhibitor of:
A2LD1, Dyrk2, IGF-I, IGF-IA, IGF-IB, IGF-IIR, IGF-IRα, IGF-IRβ, IGF2AS, IGFBP4, IGFBP6, IGFBPL1, IGFL2, INSL4, LHPP, Sval2, SVEP1, and Wip1.Activator of:
DUB2A.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
GSK1904529A, 10 mg | sc-507398 | 10 mg | $321.00 |